CN109364202A - 一种组合物及其制备方法和应用 - Google Patents
一种组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN109364202A CN109364202A CN201811378129.0A CN201811378129A CN109364202A CN 109364202 A CN109364202 A CN 109364202A CN 201811378129 A CN201811378129 A CN 201811378129A CN 109364202 A CN109364202 A CN 109364202A
- Authority
- CN
- China
- Prior art keywords
- parts
- mixture
- composition
- bamboo
- leaf extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 100
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 35
- 239000008280 blood Substances 0.000 claims abstract description 35
- 229930003944 flavone Natural products 0.000 claims abstract description 29
- 235000011949 flavones Nutrition 0.000 claims abstract description 29
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims abstract description 26
- 150000002213 flavones Chemical class 0.000 claims abstract description 25
- 241000219099 Parthenocissus quinquefolia Species 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 20
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 19
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 19
- 235000021323 fish oil Nutrition 0.000 claims abstract description 19
- 229940107071 plant stanol ester Drugs 0.000 claims abstract description 19
- 230000036039 immunity Effects 0.000 claims abstract description 6
- 241000209219 Hordeum Species 0.000 claims description 18
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 102000005606 Activins Human genes 0.000 abstract 1
- 108010059616 Activins Proteins 0.000 abstract 1
- 240000005979 Hordeum vulgare Species 0.000 abstract 1
- 239000000488 activin Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 description 25
- 230000000694 effects Effects 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- -1 flavone compound Chemical class 0.000 description 15
- 230000006870 function Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 238000011049 filling Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 229940032147 starch Drugs 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 241000563984 Ampelopsis Species 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930187677 Orientoside Natural products 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- GWOWVOYJLHSRJJ-UHFFFAOYSA-L cadmium stearate Chemical compound [Cd+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O GWOWVOYJLHSRJJ-UHFFFAOYSA-L 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- HGQSXVKHVMGQRG-UHFFFAOYSA-N dioctyltin Chemical compound CCCCCCCC[Sn]CCCCCCCC HGQSXVKHVMGQRG-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- MYXNWGACZJSMBT-VJXVFPJBSA-N isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O MYXNWGACZJSMBT-VJXVFPJBSA-N 0.000 description 1
- OYJCWTROZCNWAA-UHFFFAOYSA-N isovitexin Natural products OCC1OC(C(O)C(O)C1O)c2c(O)cc3CC(=CC(=O)c3c2O)c4ccc(O)cc4 OYJCWTROZCNWAA-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及保健品领域，具体而言，涉及一种组合物及其制备方法和应用。一种组合物，按重量份计，有效成分包括显齿蛇葡萄叶提取物50‑80份、竹叶黄酮20‑30份、大麦苗粉10‑30份、植物甾烷醇酯5‑10份、壳寡糖3‑5份、鱼油提取物2‑3份。本发明人以显齿蛇葡萄叶提取物作为主要降血脂成分，辅以竹叶黄酮，各组分协同配合增强，同时从各方面激活人体免疫力，综合调整人体机能，达到了显著的降血脂功效。
Description
技术领域
本发明涉及保健品领域，具体而言，涉及一种组合物及其制备方法和应用。
背景技术
血脂是血浆中的中性脂肪(甘油三酯)和类脂(磷脂、糖脂、固醇、类固醇)的总称，广泛存在于人体中。它们是生命细胞的基础代谢必需物质。一般说来，血脂中的主要成分是甘油三酯和胆固醇，其中甘油三酯参与人体内能量代谢，而胆固醇则主要用于合成细胞浆膜、类固醇激素和胆汁酸。
高脂血症是指血脂水平过高，可直接引起一些严重危害人体健康的疾病，如动脉粥样硬化、冠心病、胰腺炎等。目前，高脂血症成为困扰大众的一种常见疾病。
虽然较多科研人员针对这一症状做出了很多的研究，但成效仍不理想。有鉴于此，特提出本发明。
发明内容
本发明的目的在于提供一种组合物，本发明人意外发现，不同的组分配合食用，具有协同增强效果，并通过综合调整人体机能，达到了显著的降血脂的功效。
为了实现本发明的上述目的，特采用以下技术方案：
一种组合物，按重量份计，有效成分包括显齿蛇葡萄叶提取物50-80份、竹叶黄酮20-30份、大麦苗粉10-30份、植物甾烷醇酯5-10份、壳寡糖3-5份、鱼油提取物2-3份。
显齿蛇葡萄味甘、淡，性凉，具有清热解毒、祛风湿、强筋骨、消炎、镇痛等功效。民间将其幼嫩茎叶制成保健茶，用于治疗感冒发热、咽喉肿痛、黄疸型肝炎、疱疖等症已有数百年历史，是一种典型的药食两用植物。其主要有效成分为黄酮类化合物，并以二氢杨梅素含量最高。研究表明，显齿蛇葡萄中总黄酮含量为7.5％-8.3％(质量分数)，二氢杨梅素含量高达37.4％-40％，粗蛋白、水溶性蛋白、氨基酸组分、总灰分、无机营养元素、多酚、水提取物含量丰富。另含有亮氨酸、异氨酸、蛋氨酸等人体必需的17种氨基酸(人体无法自然合成)，和钾、钙、铁、锌、镁等14种微量元素，含量与当地地理、气候环境等因素有关。
其中，其有效成分二氢杨梅素具有抗氧自由基的作用，能抑制体内血栓的形成，对降血脂有较佳的效果。
此外，显齿蛇葡萄叶还具有调节血糖、保肝护肝、助消化吸收、提高免疫力、抗衰老等功效。
竹叶黄酮是从竹叶中提取出来的具有生理活性的生物黄酮，为黄色粉末，总黄酮糖苷含量在≥24％，总香豆素类内酯≥12％，包括黄酮类、内酯类和酚酸类化合物。其中，黄酮类化合物主要是碳苷黄酮，四种代表化合物为：荭草苷、异荭草苷、牡荆苷和异牡荆苷，内酯类化合物主要是羟基香豆素及其糖苷，酚酸类化合物主要是肉桂酸的衍生物，包括绿原酸、咖啡酸和阿魏酸等。
竹叶黄酮已经验证对抗心肌梗塞和保护心肌缺血，抑制凝血过程和降低血小板聚集作用，抗氧化，调节血脂等功能。
大麦苗粉是纯天然食物，无任何有害的副作用，能强化正常细胞的免疫能力，具有治疗便秘、调整肝功能，有助于血红素作用，促进体内新陈代谢以及细胞废物的排除，还具有抗氧化、减肥以及降血糖功效。
植物甾烷醇酯，来源于大豆油提取的甾醇和食用低芥酸菜籽油制取的脂肪酸甲酯。分子式：C47H84O2，分子量：681.2。性状：淡黄色粘稠油糊状。植物甾烷醇是一种新资源食品，通过抑制胆固醇在小肠内吸收，可有效降低血浆胆固醇浓度，具有降总胆固醇和低密度脂蛋白胆固醇(LDL)浓度作用。
壳寡糖是自然界中唯一带正电荷阳离子碱性氨基低聚糖，是动物性纤维素。具有提高免疫，抑制癌肿细胞生长，促进肝脾抗体形成，促进钙及矿物质的吸收，增殖双歧杆菌、乳酸菌等人体有益菌群，降血脂、降血压、降血糖、调节胆固醇，减肥，预防成人疾病等功能，广泛应用于医药、功能食品等领域。
鱼油提取物则是深海鱼类脂肪的提取物，属于油脂类，也是具有微弱鱼腥味的油状液体，但是其成分与鱼肝油截然不同，内含有ω(欧米加)－3脂肪酸(属多不饱和脂肪酸)，包括二十碳五烯酸(简称EPA)和二十二碳六烯酸(简称DHA)，这些物质能降低人体血液中低密度脂蛋白胆固醇(又称坏胆固醇)、甘油三酯，升高高密度脂蛋白胆固醇(又称好胆固醇)，从而防止动脉粥样斑块形成，并且通过影响体内其他物质代谢阻止血小板凝聚，防止血栓形成。DHA还可以通过血脑屏障，对神经传导有重要作用，是良好的健脑物质。
本发明人以显齿蛇葡萄叶提取物作为主要降血脂成分，辅以竹叶黄酮和植物甾烷醇酯，各组分协同配合增强，同时增强人体免疫力，综合调整人体机能，达到了显著的降血脂功效。
进一步地，所述有效成分还包括葫芦二烯醇1-5份。
现有的葫芦二烯醇一般认为具有一定的抗肿瘤效果，本发明人意外发现，葫芦二烯醇与组分配合，具有更快速的降血脂功效。
即本发明在上述成分的基础上，通过补加葫芦二烯醇，能进一步增强各成分的协同增强效果，达到更快的降血脂功效。
进一步地，所述有效成分还包括葫芦二烯醇2-3份。
进一步地，所述组合物为固态或液态，所述固态包括粉剂、颗粒剂。
本发明还提供了一种产品，包括上述的组合物，如该组合物可以制成保健品、功能性食品、饮料以及药物等等。
根据临床的要求，药物可制成各种剂型。进一步地，所述药物还包括药学上可接受的辅料。
进一步地，所述药学可接受的辅料包括稀释剂、赋形剂、崩解剂、填充剂、粘合剂、润滑剂、矫味剂、表面活化剂、稳定剂中的任一种或多种组合。
进一步地，所述赋形剂包括甘露醇、乳糖、淀粉、右旋糖酐、微晶纤维素中的任一种或多种组合。
进一步地，所述崩解剂包括聚乙烯吡咯烷酮、羧甲基纤维素、羧甲基纤维素钠、羟丙甲基纤维素中的任一种或多种组合。
进一步地，所述润滑剂包括滑石粉、硬脂酸镁中的任一种或两种组合。
进一步地，所述药物的剂型包括片剂、冲剂、颗粒剂、丸剂、胶囊剂中的任一种。
本发明中涉及的稀释剂如水等；填充剂如淀粉、蔗糖等；粘合剂，如淀粉浆、糊精、糖浆、蜂蜜、葡萄糖溶液、微晶纤维素、阿拉伯胶浆、明胶浆、羧甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、乙基纤维素、丙烯酸树脂、卡波姆、聚乙烯吡咯烷酮、聚乙二醇等；表面活化剂如阳离子型、阴离子型、两性离子型和非离子型；稳定剂如硬脂酸镉、硬脂酸锌、二巯基乙酸异辛酯二正辛基锡、二月桂酸二正丁基锡等等。
本发明提供的产品剂型按照本领域的常规方法制备即可。如为了将本发明的有效成分制成片剂，可以广泛使用本领域公知的各种赋形剂，包括稀释剂、粘合剂、润湿剂、崩解剂、润滑剂、助流剂。稀释剂可以是淀粉、糊精、蔗糖、葡萄糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素、硫酸钙、磷酸氢钙、碳酸钙等；湿润剂可以是水、乙醇、异丙醇等；粘合剂可以是淀粉浆、糊精、糖浆、蜂蜜、葡萄糖溶液、微晶纤维素、阿拉伯胶浆、明胶浆、羧甲基纤维素钠、甲基纤维素、羟丙基甲基纤维素、乙基纤维素、丙烯酸树脂、卡波姆、聚乙烯吡咯烷酮、聚乙二醇等；崩解剂可以是干淀粉、微晶纤维素、低取代羟丙基纤维素、交联聚乙烯吡咯烷酮、交联羧甲基纤维素钠、羧甲基淀粉钠、碳酸氢钠与枸橼酸、聚氧乙烯山梨糖醇脂肪酸酯、十二烷基磺酸钠等；润滑剂和助流剂可以是滑石粉、二氧化硅、硬脂酸盐、酒石酸、液体石蜡、聚乙二醇等。
还可以将片剂进一步制成包衣片，例如糖包衣片、薄膜包衣片、肠溶包衣片，或双层片和多层片。
如：为了将给药单元制成胶囊剂，可以将本发明的有效成分与稀释剂、助流剂混合，将混合物直接置于硬胶囊或软胶囊中。也可将有效成分先与稀释剂、黏合剂、崩解剂制成颗粒或微丸，再置于硬胶囊或软胶囊中。用于制备本发明化合物片剂的各稀释剂、黏合剂、润湿剂、崩解剂、助流剂品种也可用于制备本发明化合物的胶囊剂。
此外，如需要，也可以向药物制剂中添加着色剂、防腐剂、香料、矫味剂或其它添加剂。
本发明还提供了所述的组合物的制备方法，所述组合物为粉剂，将各组分混匀即可；
进一步地，所述混匀为：
先将显齿蛇葡萄叶提取物、竹叶黄酮和大麦苗粉混匀，得到第一混合物；
植物甾烷醇酯、壳寡糖和鱼油提取物混匀，得到第二混合物；
所述第一混合物和所述第二混合物混匀即可。
本发明还提供了另一种组合物的制备方法，所述组合物为粉剂，将各组分混匀即可；
进一步地，所述混匀为：
先将显齿蛇葡萄叶提取物、竹叶黄酮和大麦苗粉混匀，得到第一混合物；
植物甾烷醇酯、壳寡糖、葫芦二烯醇和鱼油提取物混匀，得到第二混合物；
所述第一混合物和所述第二混合物混匀即可。
本发明提供的组合物具有突出的降血脂的功效。此外，还具有显著的提升免疫力以及降血糖的功效等。
与现有技术相比，本发明的有益效果为：
(1)本发明人以显齿蛇葡萄叶提取物作为主要降血脂成分，辅以竹叶黄酮和植物甾烷醇酯，各组分协同配合增强，同时增强人体免疫力，综合调整人体机能，达到了显著的降血脂功效。
(2)本发明人意外发现，葫芦二烯醇与其他组分配合，具有更快速的降血脂功效。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述，但是本领域技术人员将会理解，下列实施例仅用于说明本发明，而不应视为限制本发明的范围。实施例中未注明具体条件者，按照常规条件或制造商建议的条件进行。所用试剂、原料或仪器未注明生产厂商者，均为可以通过市售购买获得的常规产品。
实施例1
一种组合物，由以下组分制成：
组1：显齿蛇葡萄叶提取物。
组2：按重量份计，取以下组分：显齿蛇葡萄叶提取物60份和竹叶黄酮25份，混合即得。
组3：按重量份计，取以下组分：显齿蛇葡萄叶提取物60份、竹叶黄酮25份、大麦苗粉20份、植物甾烷醇酯8份、壳寡糖4份、鱼油提取物2份，显齿蛇葡萄叶提取物、竹叶黄酮和大麦苗粉混匀，得到第一混合物；植物甾烷醇酯、壳寡糖和鱼油提取物混匀，得到第二混合物；第一混合物和第二混合物混匀即可。
组4：按重量份计，取以下组分：显齿蛇葡萄叶提取物60份、竹叶黄酮25份、大麦苗粉20份、植物甾烷醇酯8份、壳寡糖4份、鱼油提取物2份、葫芦二烯醇2份。
显齿蛇葡萄叶提取物、竹叶黄酮和大麦苗粉混匀，得到第一混合物；
植物甾烷醇酯、壳寡糖、葫芦二烯醇和鱼油提取物混匀，得到第二混合物；
第一混合物和第二混合物混匀即可。
不同组别制得的组合物进行小鼠急性毒性实验，未见明显异常。
不同组别制得的组合物进行效果检测，具体如下：
实验例a
实验动物：昆明小鼠，雌雄各半，每个体重在18-22g。分为正常对照组、模型对照组和实验组，实验组对应组1-组4共4个实验组，每个组别10只小鼠。
正常对照组以普通饲料喂养,模型对照组和实验组均以高脂饲料喂养，同时对实验组1-4小鼠灌胃组1-组4中的粉剂制成的液体,粉剂用量为0.2g/d，正常对照组和模型对照组灌等量的蒸馏水对照。每天定时灌胃、投料，自由饮水，连续6周。小鼠末次给药后，禁食不禁水16h，摘眼球取血，室温放置30min，20℃、4000r/min离心15min，分离血清，测定血脂四项指标。
血脂四项测定采用市售TC(总胆固醇)、TG(甘油三酯)、HDL-C(高密度脂蛋白胆固醇)及LDL-C(低密度脂蛋白胆固醇)试剂盒,取小鼠血清,并用自动生化分析仪进行测定。结果如表1所示。
表1小鼠血脂情况
注：与模型对照组相比，*P<0.05，**P<0.01，***P<0.001。
由表1可以看出，实验组中灌胃组合物对小鼠TC、TG和LDL-C均有一定程度的降低，对小鼠HDL-C具有一定的升高，其中，组3和组4具有显著的效果，使其各指标均保持在正常小鼠的范围内。由此可知，组3和组4提供的组合物可显著缓解由食用高脂饲料引起的TC、TG和LDL-C上升,并能使其恢复到正常水平。但是，组1和组2的效果明显与组3和组4效果差别很大，说明本实施例组3和组4的组分具有明显的协同增强效果，更有效的降低血脂含量。
实验例b
按实验例a的方法检测组3和组4的降脂速度效果，不同的是，该实验例所用的小鼠均为高脂模型动物(高脂食物饲喂6周而得)，实验过程中正常饮食，同时不同组别对应灌胃组3和组4的组合物。开始实验时测定不同动物的血脂的上述参数数值，分别于1、3、5、7、10天检测血脂的上述参数数值，统计不同天数的血脂的上升或下降百分数，结果如表2和表3所示。
表2灌胃组3组合物后小鼠血脂情况
表3灌胃组4组合物后小鼠血脂情况
注：“-”表示未检测。
从表2和表3可以看出，组4制得的组合物能更快速的降低血脂的疗效。说明本实施例组4的组分具有明显的协同增强，达到更快速的降低血脂的效果。
实施例2
一种组合物，由以下组分制成：
按重量份计，取以下组分：显齿蛇葡萄叶提取物70份、竹叶黄酮30份、大麦苗粉30份、植物甾烷醇酯9份、壳寡糖5份、鱼油提取物3份、葫芦二烯醇1份。
显齿蛇葡萄叶提取物、竹叶黄酮和大麦苗粉混匀，得到第一混合物；
植物甾烷醇酯、壳寡糖和鱼油提取物混匀，得到第二混合物；
第一混合物和第二混合物混匀即可。
实施例3
一种组合物，由以下组分制成：
按重量份计，取以下组分：显齿蛇葡萄叶提取物80份、竹叶黄酮30份、大麦苗粉30份、植物甾烷醇酯10份、壳寡糖5份、鱼油提取物3份、葫芦二烯醇3份。
显齿蛇葡萄叶提取物、竹叶黄酮和大麦苗粉混匀，得到第一混合物；
植物甾烷醇酯、壳寡糖和鱼油提取物混匀，得到第二混合物；
第一混合物和第二混合物混匀即可。
实施例4
一种组合物，由以下组分制成：
按重量份计，取以下组分：显齿蛇葡萄叶提取物50份、竹叶黄酮20份、大麦苗粉10份、植物甾烷醇酯5份、壳寡糖3份、鱼油提取物2份、葫芦二烯醇5份。
显齿蛇葡萄叶提取物、竹叶黄酮和大麦苗粉混匀，得到第一混合物；
植物甾烷醇酯、壳寡糖和鱼油提取物混匀，得到第二混合物；
第一混合物和第二混合物混匀即可。
实施例2-4制得的组合物进行小鼠实验，灌胃量同实施例1，得到，灌胃3-4天后血脂指标恢复正常值。
临床例
以实施例1组4制得的组合物进行临床使用检验效果，共实验了50人，年龄分布在40-60岁，共12人为男性，其余为女性。每日早晚一次，每次量为10g，温水冲服。跟踪统计服用效果。
血脂指标具体如下：总胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白偏高或偏低比正常值的最高值的30％以内。服用1个月后检测，均恢复正常值范围内。
食用过程中发现，同时患有血脂与血糖的患者不仅具有明显的降低血脂的功效，控制血糖的药物的用量可减半。
尽管已用具体实施例来说明和描述了本发明，然而应意识到，在不背离本发明的精神和范围的情况下可以作出许多其它的更改和修改。因此，这意味着在所附权利要求中包括属于本发明范围内的所有这些变化和修改。
Claims (10)
1.一种组合物，其特征在于，按重量份计，有效成分包括显齿蛇葡萄叶提取物50-80份、竹叶黄酮20-30份、大麦苗粉10-30份、植物甾烷醇酯5-10份、壳寡糖3-5份、鱼油提取物2-3份。
2.根据权利要求1所述的组合物，其特征在于，按重量份计，有效成分包括显齿蛇葡萄叶提取物60-70份、竹叶黄酮25-30份、大麦苗粉20-30份、植物甾烷醇酯8-9份、壳寡糖4-5份和鱼油提取物2-3份。
3.根据权利要求1所述的组合物，其特征在于，所述有效成分还包括葫芦二烯醇1-5份。
4.根据权利要求3所述的组合物，其特征在于，所述有效成分还包括葫芦二烯醇2-3份。
5.根据权利要求1-4任一项所述的组合物，其特征在于，所述组合物为固态或液态，所述固态包括粉剂、颗粒剂。
6.权利要求1-2任一项所述的组合物的制备方法，其特征在于，所述组合物为粉剂，将各组分混匀即可；
进一步地，所述混匀为：
先将显齿蛇葡萄叶提取物、竹叶黄酮和大麦苗粉混匀，得到第一混合物；
植物甾烷醇酯、壳寡糖和鱼油提取物混匀，得到第二混合物；
所述第一混合物和所述第二混合物混匀即可。
7.权利要求3-4任一项所述的组合物的制备方法，其特征在于，所述组合物为粉剂，将各组分混匀即可；
进一步地，所述混匀为：
先将显齿蛇葡萄叶提取物、竹叶黄酮和大麦苗粉混匀，得到第一混合物；
植物甾烷醇酯、壳寡糖、葫芦二烯醇和鱼油提取物混匀，得到第二混合物；
所述第一混合物和所述第二混合物混匀即可。
8.权利要求1-5任一项所述的组合物在降血脂产品中的应用。
9.权利要求1-5任一项所述的组合物在提升免疫力产品中的应用。
10.权利要求1-5任一项所述的组合物在降血糖产品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811378129.0A CN109364202B (zh) | 2018-11-19 | 2018-11-19 | 一种组合物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811378129.0A CN109364202B (zh) | 2018-11-19 | 2018-11-19 | 一种组合物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109364202A true CN109364202A (zh) | 2019-02-22 |
| CN109364202B CN109364202B (zh) | 2021-05-28 |
Family
ID=65389743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811378129.0A Active CN109364202B (zh) | 2018-11-19 | 2018-11-19 | 一种组合物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109364202B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113519846A (zh) * | 2021-07-16 | 2021-10-22 | 珠海中食果肽健康科技有限公司 | 一种能降血脂增强体内脂肪代谢的鱼油提取物多藻片及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104855979A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 降血脂非全营养配方食品 |
| CN105707863A (zh) * | 2016-03-10 | 2016-06-29 | 劲膳美生物科技股份有限公司 | 降血脂医学配方食品 |
-
2018
- 2018-11-19 CN CN201811378129.0A patent/CN109364202B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104855979A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 降血脂非全营养配方食品 |
| CN105707863A (zh) * | 2016-03-10 | 2016-06-29 | 劲膳美生物科技股份有限公司 | 降血脂医学配方食品 |
Non-Patent Citations (3)
| Title |
|---|
| 罗祖良: "罗汉果葫芦二烯醇的生物合成及葫芦烷型三萜生物活性研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
| 罗祖良等: "葫芦二烯醇及其生物合成的研究进展", 《药物生物技术》 * |
| 金旭丹: "《神奇的元素》", 31 January 2007, 内蒙古人民出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113519846A (zh) * | 2021-07-16 | 2021-10-22 | 珠海中食果肽健康科技有限公司 | 一种能降血脂增强体内脂肪代谢的鱼油提取物多藻片及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109364202B (zh) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
| JP2008174539A (ja) | 紫色の馬鈴薯を使用した肥満患者用の健康機能食品 | |
| CN103190619A (zh) | 一种鱼油亚麻籽油软胶囊及其制备方法 | |
| CN103181552A (zh) | 一种调节血脂的保健食品及其制备方法 | |
| US8394431B2 (en) | Composition of extracts from plants and the use thereof in prophylaxis or treatment of metabolism disorder of blood lipid | |
| CN102302153B (zh) | 保健组合物及其制备方法和用途 | |
| WO2017032270A1 (zh) | 预防和/或治疗心脑血管疾病的组合物 | |
| JPWO2002072123A1 (ja) | 腫瘍又はヒト乳頭腫ウイルス性疾患の予防剤又は治療剤 | |
| KR20150055876A (ko) | 체지방 감소 또는 체중 감소를 위한 조성물 | |
| CN102697982B (zh) | 一种具有辅助降血脂功能的组合物及其制备方法 | |
| WO2002045733A2 (fr) | Preparations orales ayant une action de soulagement des demageaisons ou un effet antiprurigineux | |
| KR20200136207A (ko) | 지치 추출물을 포함하는 항알러지용 조성물 | |
| CN109364202A (zh) | 一种组合物及其制备方法和应用 | |
| KR101893812B1 (ko) | 13가지 글리세리드를 포함한 의이인오일, 제제 및 그 응용 | |
| JP4629834B2 (ja) | 神経細胞賦活剤およびその利用 | |
| CN105101817B (zh) | 可食用组合物及其制备方法和包含该组合物的食品 | |
| KR20190088944A (ko) | 간세포 보호 효과 및 골 밀도 증가 효과를 갖는 쿠메스테롤 함유 발아발효콩 추출물 및 이를 포함하는 조성물 | |
| CN105558244A (zh) | 一种辅助降血脂降血糖并提高免疫力的食品及其制备方法 | |
| KR20070044198A (ko) | 푸마르산 및 푸마르산 유도체를 유효성분으로 함유하는대사증후군 치료제 | |
| CN109394977B (zh) | 一种具有降血脂功能的中药组合物及其制备方法及应用 | |
| KR102192586B1 (ko) | 아위버섯의 추출물 또는 분말을 유효성분으로 함유하는 지방간 질환 치료용 약학적 조성물 및 간기능 개선용 건강기능식품 | |
| CN112089784A (zh) | 中药组合物在制备预防、治疗动脉粥样硬化所致疾病的药物中的应用 | |
| KR101693573B1 (ko) | 갱년기 증상의 예방 또는 치료 효과가 있는 약제학적 조성물 및 그 제조방법 | |
| CN109999076A (zh) | 一种调节胆固醇逆转运的中药组合物及其应用 | |
| CN109316565A (zh) | 一种降血脂组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Chen Bo Inventor after: Jue Suyun Inventor after: Gan Xiaohui Inventor before: Chen Bo Inventor before: Jue Suyun Inventor before: Gan Xiaohui |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |